The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Article Oncology

A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer

Panagiotis A. Konstantinopoulos et al.

Summary: The combination therapy of Letrozole and Abemaciclib showed promising and durable activity in recurrent ER-positive endometrial cancers, indicating its potential as a treatment option for this subtype of cancer.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

GOG 3026 A phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study

Brian Slomovitz et al.

GYNECOLOGIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Yen-Shen Lu et al.

Summary: Ribociclib plus endocrine therapy has been shown to significantly improve the progression-free survival and overall survival of pre-/perimenopausal patients with advanced breast cancer.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study

Brian M. Slomovitz et al.

Summary: This study evaluated the efficacy and tolerability of everolimus/letrozole and medroxyprogesterone acetate/tamoxifen in the treatment of metastatic endometrial carcinoma. The results showed that both treatment regimens demonstrated clinically meaningful efficacy in patients, especially in chemotherapy-naive patients.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli et al.

Summary: This study conducted a long-term analysis of overall survival (OS) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. The results showed that treatment with palbociclib plus fulvestrant significantly improved survival compared to placebo plus fulvestrant, particularly in patients with endocrine-sensitive disease, no prior chemotherapy for advanced breast cancer, and low circulating tumor fraction.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

Gabriel N. Hortobagyi et al.

Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Oaknin et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

A. Gennari et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Add to Collection

Article Pathology

The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

Willem Jan van Weelden et al.

Summary: There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone receptor (PR) in endometrial cancer (EC), but this study identified cutoff values with the strongest prognostic impact and proposed a classification based on these values to predict distinct clinical outcomes.

HUMAN PATHOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Development of CDK4/6 Inhibitors: A Five Years Update

Alessandra Ammazzalorso et al.

Summary: Inhibition of cyclin dependent kinases 4 and 6 has shown efficacy in treating aromatase inhibitor resistant metastatic breast cancer. Recent advancements have led to the development of new selective CDK4/6 inhibitors with enhanced selectivity and treatment efficacy, aiming to reduce adverse effects.

MOLECULES (2021)

Add to Collection

Review Medicine, General & Internal

Endometrial cancer

Vicky Makker et al.

Summary: This comprehensive review provides updates on the epidemiology, pathophysiology, diagnosis, treatment, and patient quality-of-life considerations in the management of endometrial cancer. The Primer by Makker and colleagues summarizes the epidemiology, pathophysiology, diagnosis, treatment, and future research directions for endometrial cancer.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Meeting Abstract Oncology